Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Primary prevention of type 1 diabetes (T1D) requires intervention in genetically at-risk infants. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD-02, that identifies infants with a genetic high risk of T1D, enrolls these into primary prevention trials, and follows the children for beta-cell autoantibodies and diabetes. Genetic testing is offered either at delivery, together with the regular newborn testing, or at a newborn health care visits before the age of 5 months in regions of Germany (Bavaria, Saxony, Lower Saxony), UK (Oxford), Poland (Warsaw), Belgium (Leuven), and Sweden (Region Skåne). Seven clinical centers will screen around 330 000 infants. Using a genetic score based on 46 T1D susceptibility single-nucleotide polymorphisms (SNPs) or three SNPS and a first-degree family history for T1D, infants with a high (>10%) genetic risk for developing multiple beta-cell autoantibodies by the age of 6 years are identified. Screening from October 2017 to December 2018 was performed in 50 669 infants. The prevalence of high genetic risk for T1D in these infants was 1.1%. Infants with high genetic risk for T1D are followed up and offered to participate in a randomized controlled trial aiming to prevent beta-cell autoimmunity and T1D by tolerance induction with oral insulin. The GPPAD-02 study provides a unique path to primary prevention of beta-cell autoimmunity in the general population. The eventual benefit to the community, if successful, will be a reduction in the number of children developing beta-cell autoimmunity and T1D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children
Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.6285 · Cited by 1,312
Self-citationPrediction and Pathogenesis in Type 1 Diabetes
Ziegler, A.-G., & Nepom, G. T. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.018 · Cited by 346
Self-citationAge-related islet autoantibody incidence in offspring of patients with type 1 diabetes
the BABYDIAB-BABYDIET Study Group, Ziegler, A.-G., & Bonifacio, E. (2012) · Diabetologia · doi:10.1007/s00125-012-2472-x · Cited by 264
Self-citationParikka, V., Näntö-Salonen, K., Saarinen, M., Simell, T., Ilonen, J., Hyöty, H., Veijola, R., Knip, M., & Simell, O. (2012) · Diabetologia · doi:10.1007/s00125-012-2523-3 · Cited by 235
Bonifacio, E., Beyerlein, A., Hippich, M., Winkler, C., Vehik, K., Weedon, M. N., Laimighofer, M., Hattersley, A. T., Krumsiek, J., Frohnert, B. I., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002548 · Cited by 148
Self-citationRecent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
Staeva, T. P., Chatenoud, L., Insel, R., & Atkinson, M. A. (2013) · Diabetes · doi:10.2337/db12-0562 · Cited by 91
Cited by
Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany
Ziegler, A.-G., Kick, K., Bonifacio, E., Haupt, F., Hippich, M., Dunstheimer, D., Lang, M., Laub, O., Warncke, K., Lange, K., et al. (2020) · JAMA · doi:10.1001/jama.2019.21565 · Cited by 312
Self-citationUtility of genetic risk scores in type 1 diabetes
Luckett, A. M., Weedon, M. N., Hawkes, G., Leslie, R. D., Oram, R. A., & Grant, S. F. A. (2023) · Diabetologia · doi:10.1007/s00125-023-05955-y · Cited by 80
The countdown to type 1 diabetes: when, how and why does the clock start?
Ziegler, A.-G. (2023) · Diabetologia · doi:10.1007/s00125-023-05927-2 · Cited by 30
Self-citation
Metadata
- Authors
- Winkler, C., Haupt, F., Heigermoser, M., Zapardiel‐Gonzalo, J., Ohli, J., Faure, T., Kalideri, E., Hommel, A., Delivani, P., Berner, R., Kordonouri, O., Roloff, F., von dem Berge, T., Lange, K., Oltarzewski, M., Glab, R., Szypowska, A., Snape, M. D., Vatish, M., Todd, J. A., Larsson, H. E., Ramelius, A., Kördel, J. Å., Casteels, K., Paulus, J., Ziegler, A. G., Bonifacio, E., & the GPPAD Study Group
- Venue
- Pediatric Diabetes
- Publisher
- Wiley
- Published
- 2019-06-13
- Volume
- 20
- Issue
- 6
- Pages
- 720-727
- ISSN
- 1399-543X (ISSN-L)
- 1399-5448
- OpenAlex
- W2949088599
- Cited by
- 61
- References
- 6
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results. https://app.cochat.ai/papers/10.1111/pedi.12870
- The paper
- Winkler, C., Haupt, F., Heigermoser, M., Zapardiel‐Gonzalo, J., Ohli, J., Faure, T., Kalideri, E., Hommel, A., Delivani, P., Berner, R., Kordonouri, O., Roloff, F., von dem Berge, T., Lange, K., Oltarzewski, M., Glab, R., Szypowska, A., Snape, M. D., Vatish, M., . . . the GPPAD Study Group. (2019). Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD‐02 study design and first results. Pediatric Diabetes. https://doi.org/10.1111/pedi.12870
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.